I remember being a resident and having the same question about buprenorphine versus the buprenorphine and naloxone combination. Now, we have a clearer answer. The big question was whether prenatal exposure to the combination of buprenorphine and naloxone, compared to buprenorphine alone, increases the risk of adverse neonatal and maternal outcomes. I was always advised by my mentors to use buprenorphine alone in pregnant patients, as it was considered safer, with concerns that naloxone might pose a risk.
However, an article published in JAMA Psychiatry puts this debate to rest. The study compared perinatal outcomes following prenatal exposure to buprenorphine alone versus the buprenorphine and naloxone combination. The researchers evaluated the risk of congenital malformations, low birth weight, neonatal abstinence syndrome (NAS), neonatal intensive care unit (NICU) admission, preterm birth, and adjusted for confounding factors.
The findings revealed that when buprenorphine combined with naloxone was compared to buprenorphine alone, there was a lower risk of NAS, NICU admission, and being small for gestational age. The other outcome measures were similar for both groups. These results indicate that the risk is comparable, and in some cases, there are more favorable neonatal and maternal outcomes for pregnancies exposed to the buprenorphine and naloxone combination.
I can now confidently tell my former mentors that buprenorphine combined with naloxone during pregnancy appears to be a safe and effective treatment option for mothers with opioid use disorder.
Leave a Reply